Josh Bilenker ends his brief role in an un­usu­al ex­per­i­ment at Eli Lil­ly, bow­ing out as head of their Loxo can­cer R&D unit

A lit­tle more than a year since Josh Bilenker start­ed an un­usu­al ex­per­i­ment run­ning Eli Lil­ly’s can­cer re­search group fol­low­ing the $8 bil­lion sale of his start­up Loxo to the phar­ma gi­ant, the biotech en­tre­pre­neur is wrap­ping up his part in the ven­ture.

Lil­ly ex­ecs not­ed in their quar­ter­ly call to­day that Bilenker has opt­ed to leave Loxo On­col­o­gy at Lil­ly in pur­suit of oth­er, un­spec­i­fied, en­deav­ors. In his place will be Ja­cob Van Naar­den, Bilenker’s lieu­tenant among the group tapped to take up the reins of on­col­o­gy.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER